High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy

Journal of Urology

Volumn 159, Issue 1, 1998, Pages 149-153

  Joyce, Robin ^b   Fenton, Mary Anne ^b   Rode, Paola ^b   Constantine, Michael ^b   Gaynes, Lisa ^b   Kolvenbag, Geert ^b   DeWolf, William ^b   Balk, Steve ^b   Taplin, Mary Ellen ^b   Bubley, Glenn J ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Androgens; Hormones; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE;

ADULT; AGED; ANALGESIA; ANTIGEN DETECTION; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG TOLERABILITY; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0031986409     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64039-4     Document Type: Article

References (21)

1. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A. and Goodman, P. J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med., 321: 419, 1989.
2. Chang, A. Y., Bennett, J. M., Pandya, K. J., Asbury, R. and McCune, C.: A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Amer. J. Clin. Oncol., 12: 358, 1989.
3. Fossa, S. D., Hosbach, G. and Paus, E.: Flutamide in hormone-resistant prostatic cancer. J. Urol., 144: 1411, 1990.
4. Carter, H. B. and Pearson, J. D.: Evaluation of changes in PSA in the management of men with prostate cancer. Sem. Oncol., 21: 554, 1994.
5. Young, C. Y., Montogomery, B. T., Andrews, P. E., Qui, S. D., Bilhartz, D. L., and Tindall, D. J.: Hormonal regulation of prostate-specific antigen messenger RNA in the human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51: 3748, 1991.
6. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G. and Klocker, H.: Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocr., 7: 1541, 1993.
7. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J. and Kallioniemi, O. P.: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401, 1995.
8. Scher, H. I. and Kelly, W. K.: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566, 1993.
9. Olea, N., Sakabe, K., Soto, A. M. and Sonnenschien, C.: The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology, 126: 1457, 1990.
10. Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G., Keer, H. and Balk, S. P.: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl. J. Med., 332: 1393, 1995.
11. Fenton, M.-A., Shuster, T. D., Fertis, A., Taplin, M.-E., Kolvenbag, G., Bubley, G. J. and Balk, S. P.: Anti-androgen activation of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res., 3: 1383, 1997.
12. Wong, C., Kelce, W. R., Sar, M. and Wilson, E. M.: Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J. Biol. Chem., 270: 19998, 1995.
13. World Health Organization: Cancer Pain Relief. Geneva, Switzerland: W.H.O., 1986.
14. Scher, H. I., Mazumdar, M. and Kelly, W. K: Clinical trials in relapsed prostate cancer: defining the target. J. Natl. Cancer Inst., 88: 1623, 1996.
15. Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V., Schwartz, M. and Fossa, S. D.: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 11: 607, 1993.
16. Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D. and Curley, T.: Estramustine and vinblastine: use of prostate specifie antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol., 147: 931, 1992.
17. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H. and Hittmair, A.: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res., 55: 3068, 1995.
18. Yeh, S. and Chang, C.: Cloning and characterization of a specific activator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl. Acad. Sci., 93: 5517, 1996.
19. Suzuki, H., Akakura, K., Aida, S., Akimoto, S. and Shimazaki, J.: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relationship to the antiandrogen withdrawal syndrome. Prostate, 29: 152, 1996.
20. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Thibault, A., Tompkins, A., Steinberg, S., Figg, W. D., Linehan, W. M. and Myers, C. E.: Surprising activity of flutamide-withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J. Natl. Cancer Inst., 86: 222, 1994.
21. Eisenberger, M. A. and Nelson, W. G.: How much can we rely on the level of PSA as an endpoint in the evaluation of clinical trials. J. Natl. Cancer Inst., 88: 779, 1996.